Figure 4. Disease course outcome according to time above threshold dosing. Alluvial plot of the disease course outcome for patients with different durations spent above threshold dosing of oral corticosteroids (≥12.5 mg/day) for their initial episode of MOGAD. 13/17 (76%) of patients remaining above threshold dosing for more than 3 months had not experienced a relapse at last follow-up, compared with 12/48 (25%) of those who spent time above threshold dosing that was less than 3 months, and 8/45 (18%) of those who never received above threshold dosing. MOGAD, myelin oligodendrocyte glycoprotein antibody-associated disease.